Natalizumab administration in multiple sclerosis patients during active SARS-CoV-2 infection: a case series
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2377
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Natalizumab administration in multiple sclerosis patients during active SARS-CoV-2 infection: a case series ; volume:21 ; number:1 ; day:29 ; month:11 ; year:2021 ; pages:1-6 ; date:12.2021
BMC neurology ; 21, Heft 1 (29.11.2021), 1-6, 12.2021
- Urheber
-
Chisari, Clara G.
Toscano, Simona
Arena, Sebastiano
Finocchiaro, Chiara
Montineri, Arturo
Patti, Francesco
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12883-021-02421-3
- URN
-
urn:nbn:de:101:1-2022020417521361645736
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 07:32 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Chisari, Clara G.
- Toscano, Simona
- Arena, Sebastiano
- Finocchiaro, Chiara
- Montineri, Arturo
- Patti, Francesco
- SpringerLink (Online service)
Ähnliche Objekte (12)
Natalizumab May Improve Cognition and Mood in Multiple Sclerosis
Could SARS-CoV-2 herald a surge of multiple sclerosis?
Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists
Bilateral acute retinal necrosis in a patient with multiple sclerosis on natalizumab
Bruising following natalizumab infusion for relapsing-remitting multiple sclerosis: a case report
Multiple sclerosis disease activity and disability following discontinuation of natalizumab for pregnancy
Extended interval dosing strategies in multiple sclerosis: insights from natalizumab and ocrelizumab trials
GP6 rs2304166 polymorphism is associated with response to natalizumab in multiple sclerosis patients
Pediatric-onset Multiple Sclerosis treatment: a multicentre observational study comparing natalizumab with fingolimod
Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
FCGR2A rs1801274 polymorphism is associated with response to natalizumab in multiple sclerosis patients
Impact of natalizumab on patient-reported outcomes in multiple sclerosis: a longitudinal study
Natalizumab May Improve Cognition and Mood in Multiple Sclerosis
Could SARS-CoV-2 herald a surge of multiple sclerosis?
Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists
Bilateral acute retinal necrosis in a patient with multiple sclerosis on natalizumab
Bruising following natalizumab infusion for relapsing-remitting multiple sclerosis: a case report
Multiple sclerosis disease activity and disability following discontinuation of natalizumab for pregnancy
Extended interval dosing strategies in multiple sclerosis: insights from natalizumab and ocrelizumab trials
GP6 rs2304166 polymorphism is associated with response to natalizumab in multiple sclerosis patients
Pediatric-onset Multiple Sclerosis treatment: a multicentre observational study comparing natalizumab with fingolimod
Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
FCGR2A rs1801274 polymorphism is associated with response to natalizumab in multiple sclerosis patients
Impact of natalizumab on patient-reported outcomes in multiple sclerosis: a longitudinal study
Natalizumab May Improve Cognition and Mood in Multiple Sclerosis
Could SARS-CoV-2 herald a surge of multiple sclerosis?
Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists
Bilateral acute retinal necrosis in a patient with multiple sclerosis on natalizumab
Bruising following natalizumab infusion for relapsing-remitting multiple sclerosis: a case report
Multiple sclerosis disease activity and disability following discontinuation of natalizumab for pregnancy
Extended interval dosing strategies in multiple sclerosis: insights from natalizumab and ocrelizumab trials
GP6 rs2304166 polymorphism is associated with response to natalizumab in multiple sclerosis patients
Pediatric-onset Multiple Sclerosis treatment: a multicentre observational study comparing natalizumab with fingolimod
Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
FCGR2A rs1801274 polymorphism is associated with response to natalizumab in multiple sclerosis patients